Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy

BJU International

Volumn 95, Issue 4, 2005, Pages 509-512

  Carver, Brett S ^a,b   Kattan, Michael W ^a   Scardino, Peter T ^a   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Sidney Kimmel Center for Prostate and Urologic Cancers   (United States)

Author keywords

Finasteride; Gleason grade; Prostate cancer

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SURVIVAL RATE;

ENZYME INHIBITORS; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; NOMOGRAMS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; URINATION DISORDERS;

EID: 14644391613     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05375.x     Document Type: Review

References (13)

1. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. NEJM 2004; 349: 215-24
2. Ellison E, Chaung SS, Zincke H, Ferguson A, Bostwick DG. Prostate adenocarcinoma after androgen deprivation therapy. A comparative study of morphology, morphometry, immunohistochemistry, and DNA ploidy. Pathol Case Rev 1996; 2: 36-46
3. Hellstrom M, Haggman M, Brandstedt S et al. Histopathological changes in androgen-deprived localized prostatic cancer: a study in total prostatectomy specimens. Eur Urol 1993; 24: 461-5
4. Tetu B, Srigley JR, Biovin JC et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. Am J Surg Pathol 1991; 15: 111-20
5. Vaillancourt L, Tetu B, Fradet Y, Dupont A, Gomez J, Cusan L. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostate carcinoma: a randomized study. Am J Surg Pathol 1996; 20: 86-93
6. Reuter VE. Pathologic changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997; 49: 16-22
7. Bostwick DG, Ramnani D, Cheng L. Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. Urol Clin North Am 1999; 26: 465-79
8. Civantos F, Watson RB, Pinto JE. Finasteride effect on prostatic hyperplasia and prostate cancer. J Urol Pathol 1997; 6: 1-13
9. Yang XJ, Lecksell K, Short K et al. Does long-term finasteride therapy affect the histologic features of benign prostatec tissue and prostate cancer on needle biopsy. Urology 1998; 53: 696-700
10. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-71
11. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499-507
12. Brooks JR, Berman C, Nguyen H et al. Effects of castration, DES, flutamide, and the 5-alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma R-3327. Prostate 1991; 18: 215-27
13. Partin AW, Kattan MW, Subong ENP et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer: a multi-institutional update. JAMA 1997; 277: 1445-51